

Jamie T Griffin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10675412/publications.pdf>

Version: 2024-02-01

42
papers

4,152
citations

147801

31
h-index

289244

40
g-index

42
all docs

42
docs citations

42
times ranked

4917
citing authors

#	ARTICLE	IF	CITATIONS
1	Mosquito feeding behavior and how it influences residual malaria transmission across Africa. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15086-15095.	7.1	172
2	Systematic review of indoor residual spray efficacy and effectiveness against Plasmodium falciparum in Africa. Nature Communications, 2018, 9, 4982.	12.8	90
3	Modelling population-level impact to inform target product profiles for childhood malaria vaccines. BMC Medicine, 2018, 16, 109.	5.5	8
4	Predictive Malaria Epidemiology, Models of Malaria Control Interventions and Elimination. , 2018, , 1-7.		0
5	Predictive Malaria Epidemiology, Models of Malaria Transmission and Elimination. , 2018, , 1-7.		0
6	Modelling the cost-effectiveness of introducing the RTS,S malaria vaccine relative to scaling up other malaria interventions in sub-Saharan Africa. BMJ Global Health, 2017, 2, e000090.	4.7	39
7	The US President's Malaria Initiative, Plasmodium falciparum transmission and mortality: A modelling study. PLoS Medicine, 2017, 14, e1002448.	8.4	23
8	Modelling the benefits of long-acting or transmission-blocking drugs for reducing Plasmodium falciparum transmission by case management or by mass treatment. Malaria Journal, 2017, 16, 341.	2.3	11
9	Probability of Transmission of Malaria from Mosquito to Human Is Regulated by Mosquito Parasite Density in Naïve and Vaccinated Hosts. PLoS Pathogens, 2017, 13, e1006108.	4.7	104
10	Is a reproduction number of one a threshold for Plasmodium falciparum malaria elimination?. Malaria Journal, 2016, 15, 389.	2.3	10
11	Estimating the most efficient allocation of interventions to achieve reductions in Plasmodium falciparum malaria burden and transmission in Africa: a modelling study. The Lancet Global Health, 2016, 4, e474-e484.	6.3	107
12	Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa. Malaria Journal, 2016, 15, 10.	2.3	48
13	Key traveller groups of relevance to spatial malaria transmission: a survey of movement patterns in four sub-Saharan African countries. Malaria Journal, 2016, 15, 200.	2.3	43
14	Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet, The, 2016, 387, 367-375.	13.7	154
15	Potential for reduction of burden and local elimination of malaria by reducing Plasmodium falciparum malaria transmission: a mathematical modelling study. Lancet Infectious Diseases, The, 2016, 16, 465-472.	9.1	102
16	The impact of pyrethroid resistance on the efficacy and effectiveness of bednets for malaria control in Africa. ELife, 2016, 5, .	6.0	194
17	Seasonality in malaria transmission: implications for case-management with long-acting artemisinin combination therapy in sub-Saharan Africa. Malaria Journal, 2015, 14, 321.	2.3	34
18	Serology describes a profile of declining malaria transmission in Farafenni, The Gambia. Malaria Journal, 2015, 14, 416.	2.3	49

#	ARTICLE	IF	CITATIONS
19	Gradual acquisition of immunity to severe malaria with increasing exposure. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2015, 282, 20142657.	2.6	91
20	The Interaction between Seasonality and Pulsed Interventions against Malaria in Their Effects on the Reproduction Number. <i>PLoS Computational Biology</i> , 2015, 11, e1004057.	3.2	23
21	Malaria morbidity and mortality in Ebola-affected countries caused by decreased health-care capacity, and the potential effect of mitigation strategies: a modelling analysis. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 825-832.	9.1	141
22	Defining the relationship between infection prevalence and clinical incidence of <i>Plasmodium falciparum</i> malaria. <i>Nature Communications</i> , 2015, 6, 8170.	12.8	67
23	Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1450-1458.	9.1	262
24	Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. <i>Nature Communications</i> , 2014, 5, 5606.	12.8	85
25	Estimates of the changing age-burden of <i>Plasmodium falciparum</i> malaria disease in sub-Saharan Africa. <i>Nature Communications</i> , 2014, 5, 3136.	12.8	169
26	Dynamics of the Antibody Response to <i>Plasmodium falciparum</i> Infection in African Children. <i>Journal of Infectious Diseases</i> , 2014, 210, 1115-1122.	4.0	124
27	Risk factors for UK <i>Plasmodium falciparum</i> cases. <i>Malaria Journal</i> , 2014, 13, 298.	2.3	9
28	A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine. <i>BMC Medicine</i> , 2014, 12, 117.	5.5	73
29	The impact of hotspot-targeted interventions on malaria transmission: study protocol for a cluster-randomized controlled trial. <i>Trials</i> , 2013, 14, 36.	1.6	55
30	The design and statistical power of treatment re-infection studies of the association between pre-erythrocytic immunity and infection with <i>Plasmodium falciparum</i> . <i>Malaria Journal</i> , 2013, 12, 278.	2.3	3
31	A model of parity-dependent immunity to placental malaria. <i>Nature Communications</i> , 2013, 4, 1609.	12.8	46
32	The Relationship between RTS,S Vaccine-Induced Antibodies, CD4+ T Cell Responses and Protection against <i>Plasmodium falciparum</i> Infection. <i>PLoS ONE</i> , 2013, 8, e61395.	2.5	163
33	Hitting Hotspots: Spatial Targeting of Malaria for Control and Elimination. <i>PLoS Medicine</i> , 2012, 9, e1001165.	8.4	460
34	Joint estimation of the basic reproduction number and generation time parameters for infectious disease outbreaks. <i>Biostatistics</i> , 2011, 12, 303-312.	1.5	26
35	The Potential Contribution of Mass Treatment to the Control of <i>Plasmodium falciparum</i> Malaria. <i>PLoS ONE</i> , 2011, 6, e20179.	2.5	121
36	Modelling the impact of vector control interventions on <i>Anopheles gambiae</i> population dynamics. <i>Parasites and Vectors</i> , 2011, 4, 153.	2.5	177

#	ARTICLE	IF	CITATIONS
37	Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2011, 278, 1298-1305.	2.6	15
38	Protective Efficacy of Intermittent Preventive Treatment of Malaria in Infants (IPTi) Using Sulfadoxine-Pyrimethamine and Parasite Resistance. <i>PLoS ONE</i> , 2010, 5, e12618.	2.5	37
39	Reducing Plasmodium falciparum Malaria Transmission in Africa: A Model-Based Evaluation of Intervention Strategies. <i>PLoS Medicine</i> , 2010, 7, e1000324.	8.4	451
40	Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials. <i>Malaria Journal</i> , 2010, 9, 82.	2.3	52
41	Age-Patterns of Malaria Vary with Severity, Transmission Intensity and Seasonality in Sub-Saharan Africa: A Systematic Review and Pooled Analysis. <i>PLoS ONE</i> , 2010, 5, e8988.	2.5	228
42	Loss of Population Levels of Immunity to Malaria as a Result of Exposure-Reducing Interventions: Consequences for Interpretation of Disease Trends. <i>PLoS ONE</i> , 2009, 4, e4383.	2.5	86